ConductScience.org, home

Paper1373166

Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses.

Newman MJ and 7 others. J Immunol, 1992. Cited by 192 papers, by iCite.

Cite this record

ConductScience Library. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. Papers, record 1373166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1373166

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses.
PubMed
Journal
J Immunol
PubMed
Year
1992
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
192
iCite
Relative citation ratio, by iCite
4.42
iCite
Revised in PubMed
2017-11-16
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Newman MJM J
2Wu JYJ Y
3Gardner BHB H
4Munroe KJK J
5Leombruno DD
6Recchia JJ
7Kensil CRC R
8Coughlin RTR T

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adjuvants, ImmunologicMajor topic
CD8 AntigensMajor topic
OvalbuminMajor topic
SaponinsMajor topic
T-Lymphocytes, CytotoxicMajor topic
Amino Acid Sequence
Animals
Epitopes
Female
Histocompatibility Antigens Class I
Mice
Mice, Inbred C57BL
Molecular Sequence Data
Phenotype

Source PubMed

Download CSV of topics

Cited by40

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 192 citations.

PMIDTitleJournalYearIn PapersSource
42079571The challenge of one billion adjuvanted vaccine doses: evaluating scalability, sustainability, and supply capacity of Quillaja saponin QS-21 for large-scale vaccine demand.Front Immunol2026https://conductscience.org/library/papers/42079571PubMed
41409277From bark to bench: innovations in QS-21 adjuvant characterization and manufacturing.Front Immunol2025https://conductscience.org/library/papers/41409277PubMed
39083809Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy.Cancer Discov2024https://conductscience.org/library/papers/39083809PubMed
38750307A broadly applicable protein-polymer adjuvant system for antiviral vaccines.EMBO Mol Med2024https://conductscience.org/library/papers/38750307PubMed
37298177Progress towards Adjuvant Development: Focus on Antiviral Therapy.Int J Mol Sci2023https://conductscience.org/library/papers/37298177PubMed
37199661The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.Microbiol Spectr2023https://conductscience.org/library/papers/37199661PubMed
37020548Potentials of saponins-based adjuvants for nasal vaccines.Front Immunol2023https://conductscience.org/library/papers/37020548PubMed
36911719New-age vaccine adjuvants, their development, and future perspective.Front Immunol2023https://conductscience.org/library/papers/36911719PubMed
35979365Vaccine adjuvants to engage the cross-presentation pathway.Front Immunol2022https://conductscience.org/library/papers/35979365PubMed
34634664Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant.Biomaterials2021https://conductscience.org/library/papers/34634664PubMed
33824489Emerging concepts in the science of vaccine adjuvants.Nat Rev Drug Discov2021https://conductscience.org/library/papers/33824489PubMed
33807582Natural and Synthetic Saponins as Vaccine Adjuvants.Vaccines (Basel)2021https://conductscience.org/library/papers/33807582PubMed
28105029Lysosome-Dependent Activation of Human Dendritic Cells by the Vaccine Adjuvant QS-21.Front Immunol2016https://conductscience.org/library/papers/28105029PubMed
27996000Central Role of CD169+ Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01.Sci Rep2016https://conductscience.org/library/papers/27996000PubMed
27014435Quillaja Saponin Variants with Central Glycosidic Linkage Modifications Exhibit Distinct Conformations and Adjuvant Activities.Chem Sci2016https://conductscience.org/library/papers/27014435PubMed
26344621Vaccine Potentiation by Combination Adjuvants.Vaccines (Basel)2014https://conductscience.org/library/papers/26344621PubMed
25932368The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm.Springerplus2015https://conductscience.org/library/papers/25932368PubMed
21518876Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells.Proc Natl Acad Sci U S A2011https://conductscience.org/library/papers/21518876PubMed
18753338Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo.Clin Vaccine Immunol2008https://conductscience.org/library/papers/18753338PubMed
18053081The ginsenoside metabolite compound K, a novel agonist of glucocorticoid receptor, induces tolerance to endotoxin-induced lethal shock.J Cell Mol Med2008https://conductscience.org/library/papers/18053081PubMed

See all 40 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1373166

GET https://conductscience.org/api/papers/v1/1373166/cited_by?page=2